RET and medullary thyroid gland carcinoma: This classification can be applied, as our data showed, not only to patients with canonical RET mutations (exon10-11 and exon16) but also to patients with uncommon genetic alterations or even with unavailable mutational data to infer their signaling type and obtain a clue about their resemblance to an MEN2B or a MEN2A MTC.